Abstract
The activity of dizocilpine (MK-801; 0.1 and 0.3 mg/kg) administered once daily intraperitoneally (IP) was assessed in the olfactory bulbectomized rat model of depression. Olfactory bulbectomy (OB) is associated with a variety of behavioural abnormalities, such as hyperactivity in the “open field” test. Previous studies have shown that chronic administration of antidepressants can reverse this behavioural deficit. In the present study, chronic treatment with 0.1 and 0.3 mg/kg of dizocilpine (IP) antagonized the lesion-induced hyperactivity in the “open field” test. Acute treatment with dizocilpine was associated with an increase in locomotor activity in both sham-operated and OB rats, with a greater response in the sham-operated group. Following chronic treatment, this hyperactivity was found to be greater in the OB-treated animals compared with the sham-treated animals. Olfactory bulbectomy reduced serotonin (5-HT), noradrenaline (NA), and dopamine (DA) concentrations in the frontal cortex. Chronic dizocilpine administration did not alter the 5-HT or NA response. In contrast, chronic administration of dizocilpine to OB animals did attenuate the OB-related deficit in DA. In the OB-operated control animals, there was an increase in DOPAC levels. In conclusion, chronic dizocilpine administration displays antidepressant-like activity in the OB rat model of depression. However, unlike conventional antidepressants, dizocilpine does not correct the 5-HT and NA neurotransmitter deficits that occur in this model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.